Domestically Acquired Cyclosporiasis Cases in Multiple U.S. States, 2026 | HAN

• A public health emergency occurred in May 2026 involving the Bundibugyo virus (Orthoebolavirus bundibugyoense) across the Democratic Republic of the Congo and Uganda. • The disease is characterized by high mortality rates, yet it currently lacks licensed vaccines, approved therapeutics, and widespread diagnostic implementation.

• Health officials are investigating potential outbreaks of cyclosporiasis, a parasitic illness causing severe diarrhea, across the United States. • Cases have been reported in 34 states, prompting NBC News and the CDC to release a map tracking the rising infection rates.

• The Pharmaceutical Journal reported on several key healthcare developments, including progress toward a single national formulary and the potential introduction of a pharmacy performers list. • The publication highlighted a "stark lack of government response" regarding the valproate redress scheme, signaling ongoing frustration over compensation for affected individuals.

• Researchers have published a new study in Science Translational Medicine detailing how the Epstein-Barr virus triggers immune responses that cause inflammation and nervous system damage in multiple sclerosis patients. • Separately, clinical trials have demonstrated the effectiveness of a treatment that inhibits the PCSK9 protein to significantly lower dangerous LDL cholesterol levels.

• The FDA has approved Lipfendra, a new cholesterol-lowering pill developed by Merck. • Unlike traditional statins, Lipfendra is a PCSK9 inhibitor, utilizing a different mechanism to reduce cholesterol levels in patients.

• Health Minister Mark Butler confirmed that key multiple sclerosis (MS) treatments, including Ocrevus, Kesimpta, and Lemtrada, will remain subsidized on the Pharmaceutical Benefits Scheme (PBS). • The decision follows a review by an expert advisory panel, ensuring that Australians living with MS maintain affordable access to these life-changing medications.

• Boehringer Ingelheim reported first-half 2026 net sales of EUR 15.8 billion for its Human Pharma division, fueled by strong U.S. demand and the performance of JARDIANCE®. • The company expanded its R&D pipeline to approximately 80 projects, advancing key assets including the cancer immunotherapy obrixtamig and the kidney disease drug apecotrep.

• GlobalRPH has released a curated summary of top medical news topics for clinicians covering the week of July 6-12, 2026. • A primary focus of this week's reporting is the shifting geography of sexually transmitted infections (STIs) across the United States.

• Michigan health officials announced on Monday that lettuce or salad greens have been identified as the potential source of a widespread cyclosporiasis outbreak. • The illness, caused by the Cyclospora parasite transmitted via feces-contaminated food or water, has sickened thousands of people across the United States.

• A new study from the University of Southern California (USC) is investigating the causes of lung cancer in healthy, young non-smokers, specifically examining if certain healthy foods may carry unexpected risks. • Separate research highlights a critical link between adequate sleep and weight management, suggesting that poor sleep habits increase the risk of obesity-related conditions.

• Cyclosporiasis is classified as a nationally notifiable disease, requiring cases to be reported to the CDC to monitor public health trends. • The CDC, in coordination with state and federal regulatory officials, conducts year-round surveillance to identify outbreaks linked to common food sources in the U.S.